bluuebunny/crossref_metadata_2025_split huggingface dataset:
Diabetes Genes and Prostate Cancer in the Atherosclerosis Risk in Communities Study
Authors: Meyer Tamra E. , Boerwinkle Eric , Morrison Alanna C. , Volcik Kelly A. , Sanderson Maureen , Coker Ann L. , Pankow James S. , Folsom Aaron R. 
Published: February 2010

Abstract
There is a known inverse association between type 2 diabetes (T2D) and prostate cancer (PrCa) that is poorly understood. Genetic studies of the T2D-PrCa association may provide insight into the underlying mechanisms of this association. We evaluated associations in the Atherosclerosis Risk in Communities study between PrCa and nine T2D single nucleotide polymorphisms from genome-wide association studies of T2D (in CDKAL1, CDKN2A/B, FTO, HHEX, IGF2BP2, KCNJ11, PPARG, SLC30A8, and TCF7L2) and four T2D single nucleotide polymorphisms from pre–genome-wide association studies (in ADRB2, CAPN10, SLC2A2, and UCP2). From 1987 to 2000, there were 397 incident PrCa cases among 6,642 men ages 45 to 64 years at baseline. We used race-adjusted Cox proportional hazards models to estimate associations between PrCa and increasing number of T2D risk-raising alleles. PrCa was positively associated with the CAPN10 rs3792267 G allele [hazard ratio (HR) 1.20; 95% confidence interval (CI), 1.00-1.44] and inversely associated with the SLC2A2 rs5400 Thr110 allele (HR, 0.85; 95% CI, 0.72, 1.00), the UCP2 rs660339 Val55 allele (HR, 0.84; 95% CI, 0.73, 0.97) and the IGF2BP2 rs4402960 T allele (HR, 0.79; 95% CI, 0.61-1.02; blacks only). The TCF7L2 rs7903146 T allele was inversely associated with PrCa using a dominant genetic model (HR, 0.79; 95% CI, 0.65-0.97). Further knowledge of T2D gene-PrCa mechanisms may improve understanding of PrCa etiology. Cancer Epidemiol Biomarkers Prev; 19(2); 558–65
Behavioral Correlates of HPV Vaccine Acceptability in the 2007 Health Information National Trends Survey (HINTS)
Authors: Fang Carolyn Y. , Coups Elliot J. , Heckman Carolyn J. 
Published: February 2010

Abstract
The development of a prophylactic vaccine to prevent infection with oncogenic subtypes of human papillomavirus (HPV) is an important step in reducing cervical cancer incidence and mortality. However, national data indicate that only 37% of 13- to 17-year-old females have initiated the vaccine series. Prior studies have examined demographic, medical history, and psychosocial variables associated with parental HPV vaccine acceptability, although few have investigated the behavioral correlates of vaccine acceptability. The primary purpose of the current study is to report on national acceptability of the HPV vaccine among U.S. adults with female children in the household and to investigate the health behavior correlates of vaccine acceptability. Data were drawn from the 2007 Health Information National Trends Survey (HINTS). The study sample comprised 1,383 adults who reported having a female child under the age of 18 in their household (52% female, 59% white; mean age = 40 years). More than half (58%) reported they would have a daughter get the HPV vaccine, 25% were not sure, and 18% would not have a daughter vaccinated. Behavioral factors significantly associated with lower acceptance of the HPV vaccine included lack of physical activity in the past month (P = 0.002), past year use of complementary or alternative therapies (P = 0.021), and no history of smoking (P = 0.005). These results suggest that behavioral health factors may be associated with vaccine acceptability and further our understanding of how behavioral patterns may contribute to the uptake of new cancer prevention strategies. Cancer Epidemiol Biomarkers Prev; 19(2); 319–26
Prevalence of Tamoxifen Use for Breast Cancer Chemoprevention Among U.S. Women
Authors: Waters Erika A. , Cronin Kathleen A. , Graubard Barry I. , Han Paul K. , Freedman Andrew N. 
Published: February 2010

AbstractBackground: Tamoxifen can reduce the risk of developing invasive estrogen receptor–positive breast cancer by 49%, but it is unknown how many women in the United States are taking tamoxifen for primary prevention of breast cancer.Methods: Data from the years 2000 and 2005 National Health Interview Surveys were analyzed to estimate the prevalence of tamoxifen use among U.S. women for primary chemoprevention of breast cancer.Results: In 2000, ∼0.2% of U.S. women ages 40 to 79 years without a personal history of breast cancer took tamoxifen for chemoprevention (95% confidence interval, 0.13-0.31). In 2005, the prevalence was ∼0.08% (95% confidence interval, 0.03-0.17).Conclusion: The prevalence of tamoxifen use for primary prevention of breast cancer was very low in the years 2000 and 2005. Possible explanations for the low uptake are explored. Cancer Epidemiol Biomarkers Prev; 19(2); 443–6
Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients
Authors: Chung Christine H. , Seeley Erin H. , Roder Heinrich , Grigorieva Julia , Tsypin Maxim , Roder Joanna , Burtness Barbara A. , Argiris Athanassios , Forastiere Arlene A. , Gilbert Jill , Murphy Barbara , Caprioli Richard M. , Carbone David P. , Cohen Ezra E.W. 
Published: February 2010

Abstract
Background: We hypothesized that a serum proteomic profile predictive of survival benefit in non–small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) reflects tumor EGFR dependency regardless of site of origin or class of therapeutic agent.
Methods: Pretreatment serum or plasma from 230 patients treated with cetuximab, EGFR-TKIs, or chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or colorectal cancer (CRC) were analyzed by mass spectrometry. Each sample was classified into “good” or “poor” groups using VeriStrat, and survival analyses of each cohort were done based on this classification. For the CRC cohort, this classification was correlated with the tumor EGFR ligand levels and KRAS mutation status.
Results: In the EGFR inhibitor–treated cohorts, the classification predicted survival (HNSCC: gefitinib, P = 0.007 and erlotinib/bevacizumab, P = 0.02; CRC: cetuximab, P = 0.0065) whereas the chemotherapy cohort showed no survival difference. For CRC patients, tumor EGFR ligand RNA levels were significantly associated with the proteomic classification, and combined KRAS and proteomic classification provided improved survival classification.
Conclusions: Serum proteomic profiling can detect clinically significant tumor dependence on the EGFR pathway in non–small cell lung cancer, HNSCC, and CRC patients treated with either EGFR-TKIs or cetuximab. This classification is correlated with tumor EGFR ligand levels and provides a clinically practical way to identify patients with diverse cancer types most likely to benefit from EGFR inhibitors. Prospective studies are necessary to confirm these findings. Cancer Epidemiol Biomarkers Prev; 19(2); 358–65
Nonsteroidal Anti-Inflammatory Drugs and Risk for Ovarian and Endometrial Cancers in the Iowa Women's Health Study
Authors: Prizment Anna E. , Folsom Aaron R. , Anderson Kristin E. 
Published: February 2010

Abstract
Background: Several epidemiologic studies have shown inverse associations between use of nonsteroidal anti-inflammatory drugs (NSAID) and incident ovarian cancer, but the results are inconsistent. There have been only a few studies examining possible links between NSAIDs and endometrial cancer risk. We investigated associations between use of NSAIDs and incident ovarian and endometrial cancers in a prospective cohort of about 20,000 women with ages from 58 to 76 years in 1992. Participants were asked how often they used aspirin and nonaspirin NSAIDs. Over 15 years, 311 endometrial and 167 ovarian incident malignancies were identified. Multivariate-adjusted hazard ratios were estimated using Cox proportional regression.
Results: Compared with women who reported no use of aspirin, the relative risks for ovarian cancer for those who used aspirin &lt;2, 2 to 5 times, and ≥6 times per week were 0.83, 0.77, and 0.61, respectively (P trend = 0.04). We did not observe any association between nonaspirin NSAIDs use and ovarian cancer risk. Neither did we find associations between aspirin or nonaspirin NSAIDs use and risk for endometrial cancer.
Conclusions: Our results suggest a possible inverse association between frequency of aspirin use and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev; 19(2); 435–42
Association of Global Levels of Histone Modifications with Recurrence-Free Survival in Stage IIB and III Esophageal Squamous Cell Carcinomas
Authors: I Hoseok , Ko Eunkyung , Kim Yujin , Cho Eun Yoon , Han Joungho , Park Joobae , Kim Kwhanmien , Kim Duk-Hwan , Shim Young Mog 
Published: February 2010

Abstract
This study was aimed at understanding the effects of histone modifications on recurrence-free survival (RFS) after esophagectomy in esophageal squamous cell carcinoma (ESCC). The acetylation of histone H3 lysine (H3K9Ac), histone H3 lysine 18 (H3K18Ac), and histone H4 lysine 12 (H4K12Ac), and the dimethylation of histone H3 lysine 9 (H3K9diMe) and histone H4 arginine 3 (H4R3diMe) were analyzed by immunohistochemistry in 237 ESCCs. The K-means clustering algorithm was used to identify unique patterns of histone modifications. At a median follow-up of 5.1 years, 109 (46%) of 237 patients had developed recurrence of disease. Mean global levels of H3K9Ac, H3K18Ac, H3K9diMe, H4K12Ac, and H4R3diMe were 81.5%, 65.1%, 80.3%, 45.9%, and 27.4%, respectively. In the analysis of individual histones, a 1% increase in the global level of H3K18Ac in pathologic stage III worsened RFS at 1.009 times [95% confidence interval (CI), 1.001-1.016; P = 0.03], after adjusting for age, sex, and operative method. Cluster analysis also showed significant effects of histone modifications on RFS. For stage IIB cancers, Cox proportional hazards analysis showed that RFS of cluster 1, with high global levels of H3K18Ac and H4R3diMe, was 2.79 times poorer (95% CI, 1.14-6.27; P = 0.008) than that of cluster 2, with low levels. RFS for stage III cancers was also poorer in cluster 1 than cluster 2 (adjusted hazard ratio, 2.42; 95% CI, 1.10-5.34; P = 0.02). In conclusion, the present study suggests that global levels of histone modifications in ESCC may be an independent prognostic factor of RFS. Cancer Epidemiol Biomarkers Prev; 19(2); 566–73
A Systematic Review of p53 as a Prognostic Factor of Survival in Squamous Cell Carcinoma of the Four Main Anatomical Subsites of the Head and Neck
Authors: Tandon Sankalap , Tudur-Smith Catrin , Riley Richard D. , Boyd Mark T. , Jones Terence M. 
Published: February 2010

Abstract
Objectives: To summarize existing evidence about whether the presence of mutant or upregulated p53 is a prognostic factor for patients presenting with squamous cell carcinoma arising from the larynx, oropharynx, hypopharynx, or oral cavity.
Method: Relevant articles were identified using strict criteria for systematic searches. Associations between mutant or upregulated p53 versus wild-type or low/undetectable p53 in relation to overall survival and DFS were summarized by extracting or deriving hazard ratio (HR) estimates. Random-effects meta-analyses were used to account for between-study heterogeneity and to summarize the effect of p53 across studies.
Results: The meta-analyses gave a statistically significant pooled HR for overall survival in oral cavity [pooled HR, 1.48; 95% confidence interval, (95% CI), 1.03-2.11], and for disease-free survival in oral cavity (pooled HR, 1.47; 95% CI, 1.12-1.93) and in oropharynx (pooled HR, 0.45; 95% CI, 0.27-0.73). Despite attempts to limit it, between-study heterogeneity was large in the majority of meta-analyses and the prognostic value of p53 was generally inconsistent and inconclusive across studies.
Conclusion: The meta-analysis results highlight that current evidence about the prognostic value of p53 in patients with squamous cell carcinaoma of the head and neck is inconclusive. Large heterogeneity exists across studies in study-level and patient-level characteristics, making it difficult to ascertain a clear picture. Future studies are required in which p53 expression is investigated in a more standardized and biologically informative manner. In particular, prospectively planned individual patient data meta-analyses are needed to establish the prognostic importance of p53 for specific subgroups of patients undergoing specific treatments. Cancer Epidemiol Biomarkers Prev; 19(2); 574–87
Concurrent Infection with Multiple Human Papillomavirus Types: Pooled Analysis of the IARC HPV Prevalence Surveys
Authors: Vaccarella Salvatore , Franceschi Silvia , Snijders Peter J.F. , Herrero Rolando , Meijer Chris J.L.M. , Plummer Martyn ,   the IARC HPV Prevalence Surveys Study Group
Published: February 2010

AbstractTo understand viral interactions and the cross-reactivity of natural or vaccine-induced responses, we investigated whether multiple human papillomavirus (HPV) infections, particularly certain combinations of types, have the tendency to cluster together. Cervical cell samples were collected from women in the framework of the IARC HPV Prevalence Surveys. Women with a cytology diagnosis of high-grade squamous intraepithelial lesion or worse were excluded, leaving 13,961 women for this analysis. HPV DNA was assessed using a general GP5+/6+ primer–mediated PCR. HPV genotyping was done using enzyme immunoassay or reverse line blot analysis. Logistic regression with type-specific HPV positivity as an outcome was used, adjusted for age, study area, and lifetime number of sexual partners. Woman-level random effects were added to represent unobservable risk factors common to all HPV types. The observed-to-expected ratio was 1.20 (95% credible interval, 1.14-1.26) for infection with two HPV types and 1.02 (95% credible interval, 0.91-1.12) for three for more types, with the best possible adjustment. Among combinations of specific HPV types, the tendency to cluster increased with the genetic similarity of the L1 region. High observed-to-expected ratios were found for closely homologous types, including HPV33/58, 18/45, 33/35, and 31/35. The excess of multiple infections, however, was clearly evident only when enzyme immunoassay, and not reverse line blot, was used as the genotyping method. The different results by genotyping method suggest that the apparent clustering of HPV infections was an artifact of the measurement process. Further investigation is required to evaluate other widely used HPV detection methods. Cancer Epidemiol Biomarkers Prev; 19(2); 503–10
Human Papillomavirus Types 16, 18, and 31 Serostatus and Prostate Cancer Risk in the Prostate Cancer Prevention Trial
Authors: Sutcliffe Siobhan , Viscidi Raphael P. , Till Cathee , Goodman Phyllis J. , Hoque Ashraful M. , Hsing Ann W. , Thompson Ian M. , Zenilman Jonathan M. , De Marzo Angelo M. , Platz Elizabeth A. 
Published: February 2010

Abstract
Since human papillomavirus (HPV) infection was first identified as a risk factor for cervical cancer, several seroepidemiologic and tissue-based studies have investigated HPV in relation to prostate cancer, another common genitourinary malignancy, with mixed results. To further inform this potential association, we conducted a large, prospective investigation of HPV types 16, 18, and 31 in relation to risk of prostate cancer in the Prostate Cancer Prevention Trial. Cases were a sample of men diagnosed with prostate cancer after visit 2 or on their end-of-study biopsy (n = 616). Controls were men not diagnosed with prostate cancer during the trial or on their end-of-study biopsy (n = 616). Controls were frequency matched to cases by age, treatment arm, and family history of prostate cancer. Sera from visit 2 were tested for IgG antibodies against HPV types 16, 18, and 31. No associations were observed for weak or strong HPV-16 [odds ratio (OR), 0.94; 95% confidence interval (95% CI), 0.53-1.64 and OR, 1.07; 95% CI, 077-1.48, respectively], HPV-18 (OR, 0.75; 95% CI, 0.27-2.04 and OR, 0.87; 95% CI, 0.47-1.63, respectively), or HPV-31 seropositivity (OR, 0.76; 95% CI, 0.45-1.28 and OR, 1.15; 95% CI, 0.80-1.64, respectively) and risk of prostate cancer. Considering this finding in the context of the HPV and prostate cancer literature, HPV does not appear to be associated with risk of prostate cancer, at least by mechanisms proposed to date, and using epidemiologic designs and laboratory techniques currently available. Cancer Epidemiol Biomarkers Prev; 19(2); 614–8
Colorectal Cancer Susceptibility Quantitative Trait Loci in Mice as a Novel Approach to Detect Low-Penetrance Variants in Humans: A Two-Stage Case-Control Study
Authors: Fernández-Rozadilla Ceres , Tarrío Rosa , Clofent Juan , de Castro Luisa , Brea-Fernández Alejandro , Bessa Xavier , Abulí Anna , Andreu Montserrat , Jover Rodrigo , Xicola Rosa , Llor Xavier , Castells Antoni , Castellví-Bel Sergi , Carracedo Angel , Ruiz-Ponte Clara ,   for the Gastrointestinal Oncology Group of the Spanish Gastroenterological Association
Published: February 2010

Abstract
Thirty-five percent of colorectal cancer (CRC) susceptibility is thought to be attributable to genetics, but only a small proportion of the cases (&lt;6%) can be explained by highly penetrant mutations. The rest of the susceptibility could be explained by a number of low-penetrance variants following a polygenic model of inheritance. Genetic modeling in rodents has been a successful tool for the unraveling of the genetic basis of diseases. The investigation of mouse quantitative trait loci led to the discovery of 15 “susceptibility to colorectal cancer” (Scc) loci. Thus, we aimed to analyze the human-mouse syntenic regions defined by these Scc loci and select human candidate genes within. Twenty-one genes were chosen and their single-nucleotide polymorphisms were tested as possible low-penetrance variants predisposing to CRC risk. Our most strongly associated single-nucleotide polymorphism, rs954353, seems to be in the 5′ region of the CYR61 gene, which could implicate it in terms of the cis-regulation of the gene. CYR61 has been proposed as a connection point among signaling pathways and a probable marker for early CRC detection. However, we could not replicate the association. Despite our negative results, we believe that our candidate gene selection strategy could be quite useful in the future determination of variants predisposing to disease. Cancer Epidemiol Biomarkers Prev; 19(2); 619–23
One Size Does Not Fit All: Differences in HPV Knowledge between Haitian and African American Women
Authors: Kobetz Erin , Dunn Mendoza Angela , Menard Janelle , Finney Rutten Lila , Diem Joshua , Barton Betsy , Kornfeld Julie , McKenzie Nathalie 
Published: February 2010

Abstract
Background: Historically, all black persons, regardless of ancestry or country of origin, have been categorized as one group for cancer research and control efforts. This practice likely masks variability in exposure to determinants of disease, as well as in risk of cancer incidence and mortality. The current study examines potential differences in knowledge of human papilloma virus (HPV) between Haitian women living in Little Haiti, Miami, Florida, and a national sample of predominately African American women.
Methods: Data for Haitian women were collected in 2007 as part of an ongoing community-based participatory research initiative in Little Haiti. For purposes of comparison, we used data from a largely African American subsample of the 2007 Health Information National Trends Survey (HINTS). These data sources used identical items to assess HPV knowledge, providing a unique opportunity to examine how this outcome may vary between two very distinct populations who are often grouped together for research and disease surveillance.
Results: Relative to the HINTS sample, Haitian women were far less likely to have heard about HPV.
Conclusions: Study data highlight important differences in Haitian and African American women's knowledge of HPV, a known determinant of cervical cancer risk. Such findings suggest that continuing to classify persons of similar phenotype but different cultural backgrounds and lifetime exposures as one group may preclude opportunity to understand, as well as attenuate, health disparity. Cancer Epidemiol Biomarkers Prev; 19(2); 366–70
Biomechanical Evaluation of the Acromioclavicular Capsular Ligaments and Reconstruction with an Intramedullary Free Tissue Graft
Authors: Freedman Jason A. , Adamson Gregory J. , Bui Christopher , Lee Thay Q. 
Published: February 2010

Background Multiple techniques have been reported to treat chronic acromioclavicular joint injuries. However, many have failed to restore native stability, and few have addressed reconstructing the acromioclavicular ligaments. Hypothesis An intramedullary free semitendinosus graft reconstruction of the acromioclavicular ligaments will demonstrate joint stability comparable with that of the intact acromioclavicular joint. Study Design Controlled laboratory study. Methods Six matched pairs of cadaveric specimens with only the acromioclavicular capsule/ligament intact were tested at 10 N and 15 N in the anteroposterior and superoinferior directions under acromioclavicular joint compression loads of 10 N, 20 N, and 30 N. One of each pair randomly underwent reconstruction of the acromioclavicular ligaments with an intramedullary free semitendinosus graft, and the translational testing was repeated. Both the intact and reconstructed specimens then underwent load-to-failure testing via superior clavicle distraction at a rate of 50 mm/min. Results The reconstructed specimens reproduced the stability of the intact specimens during all translational and joint compression load trials. Progressively decreased translation was observed for the reconstructed specimens that reached statistical significance (P < .05) in the anteroposterior direction at 10 N of joint compression under 10-N and 15-N translation loads and in the superoinferior direction at 10 N of joint compression and 10-N translational load. With regard to load-to-failure testing, the reconstructed specimens demonstrated significantly lower (P < .05) values for linear stiffness, yield load, ultimate load, and energy absorbed, ranging from 40% to 48% of the values for the intact specimens. Conclusion Intramedullary free semitendinosus graft reconstruction of the acromioclavicular ligaments reproduced anteroposterior and superoinferior translational stability and partially reproduced load-to-failure characteristics. Clinical Relevance When surgical intervention after higher grade acromioclavicular joint injuries is required, reconstruction of the acromioclavicular ligaments with an intramedullary free semitendinosus graft, in addition to reconstructing the coracoclavicular ligaments, may result in improved stability of the joint complex, improved maintenance of joint reduction, and increased patient satisfaction.